Breadcrumb

What's New at the RI-MUHC ?

MI4 announces redefined scope: How microbes shape human health and disease, from molecules to patients to populations

Five years in, the McGill Interdisciplinary Initiative in Infection and Immunity...

Triple-negative breast cancer: the RI-MUHC enrolls first patients in international Phase 3 clinical trial

The first participants in this large study were recently selected at the Cedars Cancer Centre of the MUHC.

Researchers discover how brain cells may be hardwired for vulnerability to deadly childhood brain tumour

A clearer understanding of how brain tumours originate during brain development is paving the way for improved therapies against pediatric high-grade gliomas, the leading cause of cancer-related deaths in children and young adults.

Happy first anniversary to the Quebec SmartCare Consortium!

Led by the Opal group at the RI-MUHC, the consortium has already made advances in data infrastructure and governance, as well as improving...

$2 million USD to investigate new approaches for prostate cancer treatment

RI-MUHC researcher David P. Labbé and a team of international collaborators will investigate the mechanisms...

RI-MUHC and McGill awarded $5.1 million for infectious disease research

A new grant from the Canada Foundation for Innovation will invest in leading edge Containment Level 3...

Helping young adults achieve type 2 diabetes remission

In a collaboration with British researchers, Dr. Kaberi Dasgupta is leading a clinical trial that combines supervised exercise with meal...

The 2022 RI-MUHC Annual Report is online!

An invitation from Dr. Rhian Touyz

Quebec study on long COVID seeking participants

Purpose is to understand post-COVID symptom evolution and impact on patients’ lives

Learn more about the RI-MUHC